TScan received an upfront payment of $30 million and is expected to make more than $500 million in development and commercial milestone payments.
Collaboration Combines TScan’s Proprietary Target Discovery Platform with Amgen’s Inflammation Therapies Expertise and Research Capabilities
Amgen (Nasdaq: AMGN) and TScan Therapeutics, Inc. (Nasdaq: TCRX) today announced a multi-year collaboration to identify antigens recognized by T cells in patients with Crohn’s disease using TargetScan, TScan’s proprietary target discovery platform.
All things considered, this is one of MicroCap’s largest deals for a biopharmaceutical company. As many of you know, companies of this size in this space are typically not profitable and focus primarily on research and development until a drug or technology is fully approved and commercially viable. is placed.
Important to note in this transaction between TScan and Amgen is that the cash milestone will secure the cash runway, including the potential for TCRX to become commercially viable and profitable. That is.
Below is a descriptive breakdown of the press release for those with no background or knowledge in the field to better understand.
Amgen and TScan Therapeutics are collaborating to find new treatments for Crohn’s disease, a chronic condition that causes inflammation in the gut. TScan has a unique platform called TargetScan that can identify proteins recognized by the immune system of sick people. Amgen plans to use this information to develop new drugs to treat Crohn’s disease.
As part of the deal, TScan will receive an upfront payment of $30 million from Amgen and could earn more than $500 million if the partnership is successful. Amgen will have the right to develop and commercialize new medicines through this collaboration.
To discover the inside scoop on TCRX, enter your email in the box below and subscribe to Microcapdaily.com today.
The two companies will cover the cost of research, allowing Amgen to expand the partnership to include another disease called ulcerative colitis. This partnership could lead to new and better treatments for people with Crohn’s disease who currently have limited options to manage their symptoms.
Here are some blurbs: management team:
“Anti-inflammatory drugs have traditionally been the standard of care for patients suffering from inflammatory bowel disease, but they often lack efficacy and durability,” said Dr. Raymond DeShayes, senior vice president of global research at Amgen. Stated. “TScan’s platform offers a best-in-class approach to identifying unconventional drug targets, enabling the development of potential first-in-class therapeutics that address unmet medical needs.”
“We are excited to apply our target discovery platform to the autoimmune field,” said Dr. Gavin McBeath, Acting Chief Executive Officer and Chief Scientific and Operating Officer of TScan. “Our TargetScan platform has been extended to identify MHC class II targets of CD4+ T cells and is well suited for the discovery of antigens targeted by the immune system in inflammatory bowel disease. We look forward to developing the value of our platform both in our partnership with Amgen and in other autoimmune diseases.”
What is the retail industry saying?
As usual, with a profit of about 135%, you can probably guess that retail is all over. Nearly every investor on the internet looks to stocks for potential entry points using various day trading techniques.
Interestingly, some traders were surprised that they were able to place such a large amount of trades so early in the day. Looking at last month’s chart, the average volume was relatively low, sometimes trading as low as 5,000 shares per day. This is a significant change compared to approximately 27 million shares traded at the time of this writing.
$TCRX #TCRX It’s a nice wake-up call. Look at the tests that crossed 5.47 to 6.25. pic.twitter.com/FvoAYEFslG
— APFK_ASIAN Picasso. (@FLiPTek81) May 9, 2023
$TCRX 1000% 30m prepaid 500m worth the deal!
— Shana (@shanazaman) May 9, 2023
$TCRX ✅✅ Great return 75% profit for me
—Ethio-TradE (@alemcharity) May 9, 2023
$TCRX I guess they haven’t finished pranking people yet. When I woke up, it looked dead, bam!
— Madaz (@madaznfootballr) May 9, 2023
$LCID Large buyers confirm the order flow. +ve Check the size by counting the number of deltas. $PLTR $MOBQ $IDEX $CLRO $PYPL $TSLA $FFIE $AMD $TCRX $SOXL $SQQQ $TQQQ $NVAX $ plug $ENSC $BOIL $Zera $NKLA $CVNA $AAPL pic.twitter.com/d0RaG1xvQl
— Trading Time Traveler Karlsin (@StockMarketMcro) May 9, 2023
We’ll keep you updated on TCRX as more details become available. Make sure you subscribe to Microcapdaily to find out what’s happening at TCRX.
Disclosure: I received no compensation for this article/video. MicroCap Daily is not an investment advisor. This article/video does not provide investment advice. Always do your research and make your own investment decisions or consult your local financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold any securities. This article/video is our opinion and is for informational and educational purposes only and does not constitute investment advice. Past performance is not indicative of future performance.
Image by Gerd Altmann from Pixabay